- Home
- POR vs KYMR Comparison
POR vs KYMR Comparison
Compare POR & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- KYMR
- Stock Information
- Founded
- POR 1889
- KYMR 2015
- Country
- POR United States
- KYMR United States
- Employees
- POR N/A
- KYMR N/A
- Industry
- POR Electric Utilities: Central
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- POR Utilities
- KYMR Health Care
- Exchange
- POR Nasdaq
- KYMR Nasdaq
- Market Cap
- POR 4.7B
- KYMR 4.3B
- IPO Year
- POR N/A
- KYMR 2020
- Fundamental
- Price
- POR $47.68
- KYMR $58.38
- Analyst Decision
- POR Hold
- KYMR Strong Buy
- Analyst Count
- POR 12
- KYMR 19
- Target Price
- POR $46.91
- KYMR $68.95
- AVG Volume (30 Days)
- POR 1.3M
- KYMR 664.8K
- Earning Date
- POR 10-31-2025
- KYMR 11-04-2025
- Dividend Yield
- POR 4.39%
- KYMR N/A
- EPS Growth
- POR N/A
- KYMR N/A
- EPS
- POR 2.78
- KYMR N/A
- Revenue
- POR $3,511,000,000.00
- KYMR $43,735,000.00
- Revenue This Year
- POR $5.06
- KYMR $60.88
- Revenue Next Year
- POR $4.84
- KYMR N/A
- P/E Ratio
- POR $17.24
- KYMR N/A
- Revenue Growth
- POR 5.09
- KYMR N/A
- 52 Week Low
- POR $39.55
- KYMR $19.45
- 52 Week High
- POR $48.40
- KYMR $63.96
- Technical
- Relative Strength Index (RSI)
- POR 75.37
- KYMR 50.56
- Support Level
- POR $44.55
- KYMR $55.66
- Resistance Level
- POR $46.62
- KYMR $61.21
- Average True Range (ATR)
- POR 0.80
- KYMR 3.02
- MACD
- POR 0.16
- KYMR -0.48
- Stochastic Oscillator
- POR 85.99
- KYMR 38.46
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 100 megawatts of energy storage.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.